IL144055A0 - 4-(heterocyclylsulfonamido)-5-methoxy-6- (2-methoxyphenoxy)-2-phenyl-or pyridylpyrimidines as endothelin receptor antagonists - Google Patents

4-(heterocyclylsulfonamido)-5-methoxy-6- (2-methoxyphenoxy)-2-phenyl-or pyridylpyrimidines as endothelin receptor antagonists

Info

Publication number
IL144055A0
IL144055A0 IL14405500A IL14405500A IL144055A0 IL 144055 A0 IL144055 A0 IL 144055A0 IL 14405500 A IL14405500 A IL 14405500A IL 14405500 A IL14405500 A IL 14405500A IL 144055 A0 IL144055 A0 IL 144055A0
Authority
IL
Israel
Prior art keywords
heterocyclylsulfonamido
pyridylpyrimidines
methoxyphenoxy
methoxy
phenyl
Prior art date
Application number
IL14405500A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL144055A0 publication Critical patent/IL144055A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL14405500A 1999-01-18 2000-01-10 4-(heterocyclylsulfonamido)-5-methoxy-6- (2-methoxyphenoxy)-2-phenyl-or pyridylpyrimidines as endothelin receptor antagonists IL144055A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99100784 1999-01-18
PCT/EP2000/000103 WO2000042035A1 (en) 1999-01-18 2000-01-10 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
IL144055A0 true IL144055A0 (en) 2002-04-21

Family

ID=8237359

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14405500A IL144055A0 (en) 1999-01-18 2000-01-10 4-(heterocyclylsulfonamido)-5-methoxy-6- (2-methoxyphenoxy)-2-phenyl-or pyridylpyrimidines as endothelin receptor antagonists
IL144055A IL144055A (en) 1999-01-18 2001-06-28 4 - (Hydrocyclicsulfonamide) - 5 - Methoxy- 6– (2 - Methoxyphenox) - 2 - Phenyl - Pyridylperimides

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144055A IL144055A (en) 1999-01-18 2001-06-28 4 - (Hydrocyclicsulfonamide) - 5 - Methoxy- 6– (2 - Methoxyphenox) - 2 - Phenyl - Pyridylperimides

Country Status (31)

Country Link
US (1) US6242601B1 (ja)
EP (1) EP1149091B1 (ja)
JP (1) JP3983477B2 (ja)
KR (1) KR100478797B1 (ja)
CN (1) CN1340049A (ja)
AR (1) AR029879A1 (ja)
AT (1) ATE389648T1 (ja)
AU (1) AU763112B2 (ja)
BR (1) BR0007595A (ja)
CA (1) CA2359363C (ja)
CO (1) CO5150187A1 (ja)
CZ (1) CZ20012546A3 (ja)
DE (1) DE60038365D1 (ja)
ES (1) ES2301476T3 (ja)
GC (1) GC0000248A (ja)
HR (1) HRP20010515A2 (ja)
HU (1) HUP0200021A3 (ja)
IL (2) IL144055A0 (ja)
MA (1) MA27124A1 (ja)
MY (1) MY121136A (ja)
NO (1) NO322800B1 (ja)
NZ (1) NZ512662A (ja)
PE (1) PE20001421A1 (ja)
PL (1) PL350093A1 (ja)
RU (1) RU2224757C2 (ja)
TR (1) TR200102071T2 (ja)
TW (1) TWI284642B (ja)
UY (1) UY25904A1 (ja)
WO (1) WO2000042035A1 (ja)
YU (1) YU50001A (ja)
ZA (1) ZA200105279B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
IL144144A0 (en) * 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
BRPI0116237B8 (pt) 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MEP36208A (en) * 2001-12-03 2011-02-10 Bayer Corp Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
AU2003210969A1 (en) * 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
PT1580188E (pt) * 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
CA2475703C (en) 2002-02-11 2016-12-20 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2003068229A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CA2507334C (en) * 2002-12-02 2013-05-07 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US7269460B2 (en) * 2003-02-28 2007-09-11 Medtronic, Inc. Method and apparatus for evaluating and optimizing ventricular synchronization
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20070020704A1 (en) 2003-05-20 2007-01-25 Scott Wilhelm Diaryl ureas with kinase inhibiting activity
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
RU2435585C2 (ru) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
ATE537144T1 (de) 2006-05-29 2011-12-15 Nicox Sa Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US10287263B2 (en) * 2014-11-21 2019-05-14 Daikin Industries, Ltd. Fluorinated unsaturated cyclic carbonate and process for producing same
CN109260164A (zh) * 2018-10-07 2019-01-25 威海贯标信息科技有限公司 一种阿伏生坦片剂组合物
CN112778215B (zh) * 2021-01-29 2023-06-20 中国医科大学 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用
CN112898208B (zh) * 2021-01-29 2023-06-20 中国医科大学 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用
TW202329952A (zh) 2021-12-17 2023-08-01 瑞士商愛杜西亞製藥有限公司 克拉生坦(clazosentan)二鈉鹽之製備方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (ja) * 1994-12-20 1997-08-21 Hoffmann La Roche
EP0882719B1 (en) * 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same

Also Published As

Publication number Publication date
NO20013454L (no) 2001-07-12
MY121136A (en) 2005-12-30
YU50001A (sh) 2004-03-12
RU2224757C2 (ru) 2004-02-27
HUP0200021A3 (en) 2003-01-28
AR029879A1 (es) 2003-07-23
CZ20012546A3 (cs) 2001-12-12
EP1149091B1 (en) 2008-03-19
BR0007595A (pt) 2001-10-16
CN1340049A (zh) 2002-03-13
DE60038365D1 (en) 2008-04-30
WO2000042035A1 (en) 2000-07-20
UY25904A1 (es) 2001-07-31
PL350093A1 (en) 2002-11-04
PE20001421A1 (es) 2000-12-18
NZ512662A (en) 2003-11-28
JP2002534518A (ja) 2002-10-15
HRP20010515A2 (en) 2003-06-30
NO322800B1 (no) 2006-12-11
ATE389648T1 (de) 2008-04-15
TWI284642B (en) 2007-08-01
IL144055A (en) 2007-07-24
CO5150187A1 (es) 2002-04-29
US6242601B1 (en) 2001-06-05
NO20013454D0 (no) 2001-07-12
JP3983477B2 (ja) 2007-09-26
HUP0200021A2 (hu) 2002-05-29
CA2359363A1 (en) 2000-07-20
MA27124A1 (fr) 2005-01-03
AU763112B2 (en) 2003-07-10
TR200102071T2 (tr) 2002-03-21
ZA200105279B (en) 2002-10-07
GC0000248A (en) 2006-11-01
KR20010094746A (ko) 2001-11-01
KR100478797B1 (ko) 2005-03-24
EP1149091A1 (en) 2001-10-31
ES2301476T3 (es) 2008-07-01
CA2359363C (en) 2006-03-14
AU2663000A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
IL144055A0 (en) 4-(heterocyclylsulfonamido)-5-methoxy-6- (2-methoxyphenoxy)-2-phenyl-or pyridylpyrimidines as endothelin receptor antagonists
IL155805A0 (en) Novel sulfamides and their use as endothelin receptor antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
EP1254116A4 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
EP1229910A4 (en) integrin
EP1194151A4 (en) ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1252162A4 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
EP1248607A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
AU9259801A (en) Alpha v integrin receptor antagonists
IL148043A0 (en) Novel integrin receptor antagonists
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
IL145051A0 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
AU2002226048A1 (en) Urotensin-ii receptor antagonists
EP1351687A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
HK1047750A1 (zh) 趨化因子受體拮抗劑
EG24179A (en) Vitronectin receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
EP1169042A4 (en) DIBENZO-AZEPINE DERIVATIVES AS ANTAGONISTS OF THE ALPHA V INTEGRIN RECEPTOR
GB0026327D0 (en) Thrombin receptor antagonists
AU9088401A (en) Alpha v integrin receptor antagonists
AU2512800A (en) Alpha1-adrenergic receptor antagonists
SI1187592T1 (sl) Antagonisti alfa V integrinskega receptorja

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees